bluebird bio, Inc. (Nasdaq: BLUE) announced on August 20, 2024, that it received notices from Nasdaq stating it is not in compliance with Nasdaq Listing Rule 5250(c)(1). This is due to the company’s failure to file its Quarterly Reports on Form 10-Q for the quarters ending March 31, 2024, and June 30, 2024.
The notices do not immediately affect the listing or trading of the company’s stock on Nasdaq.
Earlier, on April 26, 2024, bluebird bio had disclosed non-compliance with the Rule because of a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023. The company submitted a plan to Nasdaq to regain compliance by October 14, 2024, and must file the Q1 and Q2 2024 Form 10-Q reports within this period, with an update due by September 4, 2024.
On March 26, 2024, bluebird bio announced it would restate its consolidated financial statements for 2022 and the first three quarters of 2023, causing delays in filing the 2023 Form 10-K and the Q1 and Q2 2024 Form 10-Q reports. The company is working to complete these filings.
About bluebird bio, Inc.
bluebird bio is dedicated to curative gene therapies, aiming to provide patients and their families with more “bluebird days.” Founded in 2010, bluebird has pioneered gene therapy, securing FDA approvals for three therapies in under two years. The company focuses on severe genetic diseases and has the largest ex-vivo gene therapy data set in the field, with leading programs for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. bluebird continues to innovate and scale its gene therapy solutions, committed to advancing patient care and fostering a diverse and dedicated team.
